Day: April 5, 2023
Notice to attend Extraordinary General Meeting in Anoto Group AB (publ)
The shareholders of Anoto Group AB (publ) (the “Company”) are hereby invited to attend the Extraordinary General Meeting (the “EGM”) to be held on Thursday, 4 May 2023 at 10 a.m. at the premises of Setterwalls Advokatbyrå, Sturegatan 10 in Stockholm, Sweden.
Notification of participation
Shareholders wishing to attend the EGM mustbe entered as shareholders in the share register maintained by Euroclear Sweden AB no later than on Tuesday, 25 April 2023,
notify the Company of their intention to participate no later than on Tuesday, 2 May 2023.Attendance is to be notified by phone to +44 758 430 12 60 or by e-mail to EGM@anoto.com. The notification should state name, social security number/corporate identification number and registered number of shares. To facilitate...
Anoto resolves on a SEK 20 million directed issue and a SEK 20 million rights offering in order to strengthen financial position and in preparation for a large order from a customer of KAIT
Written by Customer Service on . Posted in Public Companies.
5 April 2023Anoto hereby informs that it is in late-stage discussions regarding a potential order of several hundred thousand pens. In order to finance a timely delivery of pens regarding the potential order and repay outstanding debt, the Board of Directors has resolved to carry out a directed share issue and a rights issue amounting to in total approximately SEK 40 million. The rights issue is guaranteed to 50 per cent and both the directed issue and the rights issue is subject to approval by an Extraordinary General Meeting.
Background and reasons
Anoto Group AB (“Anoto” or the “Company”) is in late-stage discussions with a Middle East government regarding a potential delivery of several hundred thousand pens. The potential order would also include a long-term license agreement regarding software products from Knowledge AI Holdings...
From Complexity to Clarity: CTMS Paves the Way for Better Clinical Trials
Written by Customer Service on . Posted in Mergers And Acquisitions.
SkyQuest’s Clinical Trial Management System (CTMS) market report is an excellent analysis for individuals interested in gaining insight into the valuable data, trends, and opportunities in a rapidly growing industry. Additionally, the report is written clearly and concisely, making it accessible to various audiences, from industry experts to market readers. Finally, one can gain an in-depth understanding of the primary and secondary market drivers, providing them with a comprehensive outlook of the current market situation and future projections.
Westford, USA, April 05, 2023 (GLOBE NEWSWIRE) — In 2030, the Clinical Trial Management System (CTMS) market will reportedly attain a value of USD 5.89 billion, with a projected compound annual growth rate (CAGR) of 13.50% throughout the forecast period (2023-2030). The increasing...
PGS ASA: Webcast Details for Presentation of Q1 2023 Results
Written by Customer Service on . Posted in Public Companies.
April 5, 2023 Oslo, Norway: PGS will release its Q1 2023 results on Thursday April 27, 2023 at approximately 08:00 am Central European Summer Time (CEST).
The earnings release and the earnings presentation will be published on www.newsweb.no and on PGS’ website www.pgs.com.
President & CEO Rune Olav Pedersen and EVP & CFO Gottfred Langseth will present the results the same day at 09:00 am CEST at PGS’ headquarters, Lilleakerveien 4C, Oslo, Norway.
The presentation is open to the public and will also be webcasted live. To join the webcast, copy and paste the link below into your browser, or go to PGS website www.pgs.com.
Webcast link: https://channel.royalcast.com/landingpage/hegnarmedia/20230427_7/
Webcast YouTube link:https://youtube.com/live/tDHpzo2Xp8M
A replay of the webcast will be made available on PGS’ website shortly...
Huhtamaki publishes Q1 2023 Interim Report on April 27, 2023
Written by Customer Service on . Posted in Public Companies.
HUHTAMÄKI OYJ PRESS RELEASE 5.4.2023 AT 9:00 EEST
Huhtamaki publishes Q1 2023 Interim Report on April 27, 2023
Huhtamäki Oyj will publish its Q1 2023 Interim Report on Thursday, April 27, 2023, approximately at 8:30 Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors.
Huhtamaki will arrange a combined audiocast and teleconference on the same day at 9:00 (please note the exceptional time). Huhtamaki’s CEO & President Charles Héaulmé and CFO Thomas Geust will present the results, followed by a Q&A session. The event will be held in English and it can be followed in real-time.
A link to the audiocast is available at: https://huhtamaki.videosync.fi/2023-q1
A link to the teleconference is available at: https://palvelu.flik.fi/teleconference/?id=10010470....
Nexans completes inaugural Sustainability-Linked Bond issuance
Written by Customer Service on . Posted in Public Companies.
Nexans completes inaugural Sustainability-Linked Bond issuance
_PRESS RELEASE_
Paris, April 5th 2023 – Nexans announces today the successful issuance of its inaugural euro Sustainability-Linked Bond for an aggregate nominal amount of 400 million euros with a 5-year maturity and an annual interest rate of 5.50%.
The transaction had outstanding market reception and the size has been increased to 400 million euros from 325 million euros.
This transaction underlines Nexans’ solid balance sheet as illustrated by S&P’s decision to upgrade Nexans’ credit rating outlook from stable to positive and to confirm its ‘BB+’ rating in February 2023.
Nexans’ inaugural Sustainability-Linked Bond is aligned with Nexans’ Sustainable Financing Framework which is central to the Group’s refinancing strategy and is a step in further embedding...
Mendus to participate in upcoming conferences in April 2023 and to hold investor call following Annual Report publication on April 17th
Written by Customer Service on . Posted in Public Companies.
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:Innovation for Health
Rotterdam, The Netherlands, April 6, 2023
Erik Manting, CEO of Mendus, will be part of a panel discussion on partnerships and deal-making.
https://www.hyphenprojects.nl/i4hAACR Annual Meeting 2023
Orlando, FL, USA, April 14–19, 2023
Mendus to present interim data from the ALISON trial in ovarian cancer.
https://www.aacr.org/meeting/aacr-annual-meeting-2023/Kempen’s 14th Life Sciences Conference
Amsterdam, The Netherlands, April 25-26, 2023
Mendus’ leadership team will participate and Erik Manting, CEO of Mendus, will give a presentation at the conference.
https://www.vanlanschotkempen.com/en-nl/investment-banking/equities/life-sciences-and-healthcare/life-sciences-conference Additionally,...
Notice of Annual General Meeting JLT Mobile Computers AB (publ) (Swedish only)
Written by Customer Service on . Posted in Public Companies.
Växjö, Sverige, 5:e april 2023 * * * Aktieägarna i JLT Mobile Computers AB (publ) kallas till årsstämma torsdagen den 4 maj 2023 kl. 16.00 på PM & Vänner Hotell, Västergatan 10 i Växjö.
Rätt till deltagande
Rätt att delta i stämman har den som dels upptagits som aktieägare i den av Euroclear Sweden AB förda aktieboken avseende förhållandena tisdagen den 25 april 2023, dels anmält sin avsikt att delta senast fredagen den 28 april 2023.
Aktieägare som har sina aktier förvaltarregistrerade, genom bank eller annan förvaltare, måste, för att ha rätt att delta vid bolagsstämman omregistrera aktierna i eget namn. Sådan omregistrering, som kan vara tillfällig, måste vara genomförd tisdagen den 25 april 2023, vilket innebär att aktieägare som önskar sådan omregistrering måste underrätta förvaltaren om detta i god tid före nämnda datum. Sådan...
Kitron: Notice of Annual General Meeting on 28 April 2023 at 10:00 a.m. CEST
Written by Customer Service on . Posted in Public Companies.
(2023-04-05) The Annual General Meeting of Kitron will be held on Friday 28 April 2023 at 10:00 a.m. CEST. The General Meeting will only be held as a digital meeting.
All shareholders are invited to participate online. It will not be possible to attend in person. Shareholders may also vote in advance or submit a proxy with voting instructions.
Further information on the matters on the agenda and the board of directors’ proposed resolutions are set out in the attached notice.
For further information, please contact: Cathrin Nylander, CFO, tel: +47 900 43 284 E-mail: investorrelations@kitron.com
Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The group is located in Norway, Sweden, Denmark, Lithuania, Germany,...
Notice of General Meeting and Publication of Circular
Written by Customer Service on . Posted in Public Companies.
LONDON and NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, announces that, further to its announcement on 4 April 2023, it has today posted a circular (the “Circular“) to shareholders which contains further details regarding the proposed cancellation of its ordinary shares of no par value each (“Ordinary Shares“) from listing on the standard segment of the Official List of the Financial Conduct Authority and trading on the main market for listed securities of London Stock Exchange plc and associated timetable, together with proposals to...